Skip to content

Trial Summary

This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemotherapy.



ACTRN/NCT /ethics:


Scientific title:

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Sponsor / Cooperative group:

Jiangsu HengRui Medicine Co., Ltd.

Trial & Patient Characteristics

Cancer TypeLung
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced: Metastatic or Widespread
Anticipated Start Date2020-09-11
Anticipated End Date2023-10-31

Participating Hospitals

HospitalCalvary North Adelaide Hospital
Clinical Trial CoordinatorJulie Rowe
Phone08 8239 9536
Principal InvestigatorDr Rohit Joshi
Recruitment StatusRecruiting